Melanie San Pedro-Salcedo

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

Matthew A. Gubens, Matthew Burns, Susan M. Perkins et al. · Lung Cancer · 2015 · 51 citations

Medicine, Oncology, Pharmacology +10

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies

Jessica A. Hellyer, Matthew A. Gubens, Kristen Cunanan et al. · Lung Cancer · 2019 · 21 citations

Medicine, Oncology, Pharmacology +6

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer

Christelle Clément-Duchêne, Yelena Krupitskaya, Kristen N. Ganjoo et al. · Journal of Thoracic Oncology · 2010 · 16 citations · Full text

Medicine, Oncology, Pharmacology +10

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

Iván Díaz-Padilla, Lillian L. Siu, Melanie San Pedro-Salcedo et al. · British Journal of Cancer · 2012 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy

Matthew A. Gubens, Jody C. Chuang, Wallace Akerley et al. · Journal of Thoracic Disease · 2018 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +16